Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders

 
 

Denali Therapeutics Inc. (DNLI) Add to portfolio

1m | 3m | 6m | 1y | 2y | 5y | 10yDenali Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing therapeutics for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis.

Sector: Healthcare
Industry: Biotechnology

CEO: Ryan J. Watts
https://www.denalitherapeutics.com
Price: $20.77 Metrics
OS: 95.0 M -30 % ROE
Market cap: $1.97 B -31 % ROIC
Net cash: $517 M $5.45 per share
EV: $1.46 B

 
TTM Valuation
EBITDA ($137) M
EBIT ($145) M
EPS ($2.76)

Recent News + Filings   (All items)

Financial Summary   (All financials)
In millions, except per share itemsDec-31-17Dec-31-16Dec-31-15
Revenues74.575.711.6
            Revenue growth-1.6%554.2% 
Cost of goods sold90.187.416.7
Gross profit-15.7-11.7-5.1
            Gross margin-21.1%-15.5%-44.1%
General and administrative15.711.75.1
EBIT-90.1-87.4-16.7
            EBIT margin-121.1%-115.5%-144.1%
Pre-tax income-88.2-86.7-16.8
Income taxes0.00.00.0
            Tax rate0.0%0.0%0.0%
Net income-88.2-86.7-16.8
            Net margin-118.4%-114.5%-145.1%
 
Diluted EPS($5.89)($13.49)($5.58)
Shares outstanding (diluted)15.06.43.0
 
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.

Rocket Data Systems, Inc. © 2018 | Contact Us | Data Disclaimer | Terms of Use | Privacy